Skip to main content

12.02.2019 | Original Article | Ausgabe 5/2019

Virchows Archiv 5/2019

β-Catenin nuclear expression discriminates deep penetrating nevi from other cutaneous melanocytic tumors

Virchows Archiv > Ausgabe 5/2019
Arnaud de la Fouchardière, Claire Caillot, Julien Jacquemus, Emeline Durieux, Aurélie Houlier, Véronique Haddad, Daniel Pissaloux
Wichtige Hinweise
Virchows Archiv conforms to the ICMJE recommendation for qualification of authorship. The ICMJE recommends that authorship be based on the following four criteria:
• Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
• Drafting the work or revising it critically for important intellectual content; AND
• Final approval of the version to be published; AND
• Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


Recent advances in genomics have improved the molecular classification of cutaneous melanocytic tumors. Among them, deep penetrating nevi (DPN) and plexiform nevi have been linked to joint activation of the MAP kinase and dysregulation of the β-catenin pathways. Immunohistochemical studies have confirmed cytoplasmic and nuclear expression of β-catenin and its downstream effector cyclin D1 in these tumors. We assessed nuclear β-catenin immunohistochemical expression in a large group of DPN as well as in the four most frequent differential diagnoses of DPN: “blue” melanocytic tumors, Spitz tumors, nevoid and SSM melanomas, and pigmented epithelioid melanocytomas (PEM). Nuclear β-catenin expression was positive in 98/100 DPN and 2/16 of melanomas (one SSM and one nevoid melanoma with a plexiform clone) and was negative in all 30 Spitz, 26 blue, and 6 PEM lesions. In 41% DPN, β-catenin expression was positive in more than 30% nuclei. No differences were observed in cytoplasmic and nuclear cyclin D1 expression between these tumor groups, suggesting alternate, β-catenin-independent, activation pathways. We have subsequently studied nuclear β-catenin expression in a set of 13 tumors with an ambiguous diagnosis, for which DPN was part of the differential diagnosis. The three out of four patients showing canonical DPN mutation profiles were the only β-catenin-positive cases. We conclude that nuclear β-catenin expression, independently from CCND1 expression, in a dermal melanocytic tumor is an argument for its classification as DPN. In ambiguous cases and in early combined DPN lesions, this antibody can be helpful as a screening tool. β-Catenin is also potentially expressed in a subset of malignant melanomas with CTNNB1 mutations.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Jetzt e.Med bestellen und 100 € sparen!

Über diesen Artikel

Weitere Artikel der Ausgabe 5/2019

Virchows Archiv 5/2019 Zur Ausgabe

Neu im Fachgebiet Pathologie

01.02.2020 | Forensische Begutachtung | CME | Ausgabe 1/2020

Diagnose einer gewaltsamen Erstickung

Teil 1: Reevaluation der Spezifität makroskopischer und histomorphologischer Befunde

27.01.2020 | Schwerpunkt: Lunge | Ausgabe 1/2020

Immunhistochemiebasierte prädiktive Biomarker bei Lungenkarzinomen

27.01.2020 | Schwerpunkt: Lunge | Ausgabe 1/2020

Zytologie der primären Lungenkarzinome